Safety and effectiveness of Monovisc™ in the relief of joint pain in patients with idiopathic knee OA

Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial.

Article specifications

This clinical trial was published in 2018 in Journal of Knee Surg Sports Traumatol Arthrosc. (IF 2014: 3.053) by American specialists. The primary objective was to demonstrate the safety and effectiveness of Monovisc™ in the relief of joint pain in patients with idiopathic knee OA compared to saline injection. 369 patients (154 male, 215 female) were randomized to either Monovisc™ or saline.

 

Result

The Monovisc™ group had a significantly greater rate of patient success compared to saline. Monovisc™, a single-injection intra-articular HA device, is a safe and effective treatment for providing a clinically meaningful reduction in knee pain within 2 weeks. The results of this study support the use of a single injection of hyaluronic acid (Monovisc™) for patients with symptomatic knee OA in patients older than 45 years, as a safe and effective alternative for patients who may want an alternative treatment modality or may not be candidates for partial or total knee replacement.